Nasdaq · CIK 0001599298 · PHARMACEUTICAL PREPARATIONS
Summit Therapeutics Inc.
SMMT chart by TradingView
PRICE HISTORY
LIVE · NASDAQSMMT chart by TradingView
- REVENUE FY2024 ENDED DEC 2024
- $0.0B
- EBITDA
- $-0.2B
- FREE CASH FLOW
- $-0.1B
- EPS
- $-0.31
- GROSS MARGIN
- —
- ROIC
- —
Q1 FY24ENDED SEP 2024HOVERDRAG ACROSS ANY CHART TO SCRUB ALL 24 · 17 QUARTERS SHOWNVALUATIONGROWTHPROFITABILITY & RETURNSCASH & CAPITALBALANCE SHEET
VALUATION
what you pay for a unit of the business7 CHARTS⤢
P / E RATIO (TTM)
—
⤢
P / SALES (TTM)
—
+1433%68.5x7960.0x
⤢
P / BOOK
36.3x
+1004%1.9x36.3x
⤢
EV / EBITDA (TTM)
—
⤢
EV / REVENUE (TTM)
—
⤢
FCF YIELD (TTM)
-0.59%
+10.3pp-51.20%-0.59%
⤢
DIVIDEND YIELD (TTM)
—
GROWTH
is the business getting bigger5 CHARTS⤢
REVENUE
$0.0B
-100%⤢
EBITDA (DERIVED)
$-0.1B
$0.0B⤢
NET INCOME
$-0.1B
$0.1B⤢
EPS (DILUTED)
$-0.08
$0.01⤢
REVENUE GROWTH YOY
—
-59.3pp-100.00%623.20%
PROFITABILITY & RETURNS
what survives to the bottom, and what it earns on capital4 CHARTS⤢
FCF MARGIN
—
-2339.7pp-33903.51%-1539.81%
⤢
RETURN ON CAPITAL
—
⤢
RETURN ON EQUITY (TTM)
-29.41%
+36.9pp-791.49%-29.41%
MARGIN FUNNEL
every line is a share of the same revenue, so they read on one scale — the gaps are what each layer takes out, and net rises above operating when income arrives from outside the businessGROSS MARGIN—
OPERATING MARGIN—
NET MARGIN—
FCF MARGIN—
CASH & CAPITAL
where the money actually goes5 CHARTS⤢
FREE CASH FLOW
$-0.0B
$0.0B⤢
STOCK-BASED COMP
$0.0B
+6422%⤢
CAPITAL EXPENDITURE
$0.0B
+93%⤢
SHARES OUTSTANDING
0.73B
+665%⤢
DIVIDEND / SHARE
—
BALANCE SHEET
how much cushion there is3 CHARTS⤢
CASH & EQUIVALENTS
$0.1B
+341%⤢
TOTAL DEBT
—
⤢
DEBT / EBITDA (TTM)
—
OWNERSHIP
10 LARGEST HOLDERS · WHO OWNS THE FLOATINSTITUTIONS 15.83%INSIDERS 80.89%OTHER / RETAIL 3.28%304 INSTITUTIONAL FILERS
| HOLDER | % HELD | SHARES | VALUE | CHANGE |
|---|---|---|---|---|
| Baker Bros. Advisors, LP | 4.56% | 36.4M | $508.0M | +0.0% |
| FMR, LLC | 1.36% | 10.9M | $151.5M | -18.8% |
| Blackrock Inc. | 1.21% | 9.7M | $134.8M | +3.1% |
| Price (T.Rowe) Associates Inc | 1.04% | 8.3M | $115.6M | -11.7% |
| State Street Corporation | 0.88% | 7.0M | $98.1M | +5.9% |
| Vanguard Capital Management LLC | 0.72% | 5.7M | $79.7M | NEW |
| Vanguard Portfolio Management LLC | 0.66% | 5.2M | $73.1M | NEW |
| UBS Group AG | 0.46% | 3.7M | $51.4M | +322.7% |
| Geode Capital Management, LLC | 0.42% | 3.3M | $46.3M | +5.3% |
| Shaw D.E. & Co., Inc. | 0.28% | 2.2M | $31.3M | +439.9% |
AS OF 2026-03-31 · MOST RECENT 13F FILINGS
SOURCE → 10-K · 10-Q · 8-K / GUIDANCE · ALL FILINGS
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.